Product highlights: InVivoPlus anti-mouse CD40 Catalog #BP0016-2 of Bio X Cell

by | Sep 3, 2025 | Cancer, Disease Modelling, Drug Discovery, Immunology, in vivo Studies

IN VIVO ANTIBODIES FROM BIO X CELL

InVivoPlus anti-mouse CD40 Catalog #BP0016-2

Probing CD40 Signaling in Autoimmunity and Immuno-Oncology

CD40 is a critical costimulatory receptor for B cell activation and autoantibody production. Agonist antibodies such as FGK4.5 mimic CD154 engagement, driving B cell-mediated immune responses in both autoimmune and cancer models.

InVivoPlus anti-mouse CD40, clone FGK4.5, delivers high-quality in vivo grade performance for investigating CD40 signaling in preclinical research.

– Activates CD40 signaling
– In vivo ready and endotoxin low
– Used in autoimmunity and cancer models

Explore clone FGK4.5 to advance your immune activation studies.

All products listed on this site and sold through LAB-A-PORTER Limited are for research use only (RUO). Not for human use. Not for therapeutic or diagnostic use.

ABOUT BIO X CELL

Antibodies For In Vivo Research

Bio X Cell antibodies are formulated for in vivo experiments and used extensively in animal models of human disease. They feature greater than 95% purity, ultra-low endotoxin levels, and are presevative, stabilizer, and carrier protein-free. Bio X Cell has developed a wide range of antibodies for immuno-oncology, immunology, and neuroscience research. Their products are cited in over 15,000 publications that detail a broad range of applications, including in vivo cell-specific depletion, cytokine neutralization, immune checkpoint blockade, and more.

 

    • Exceptional Purity
    • Pathogen Free
    • Ultra-low Endotoxin Level
    • Advanced Binding Validation
    • Low Protein Aggregation
    • Marching Isotype Control Antibodies

All products listed on this site and sold through LAB-A-PORTER Limited are for research use only (RUO). Not for human use. Not for therapeutic or diagnostic use.

LAB-A-PORTER IS THE EXCLUSIVE DISTRIBUTOR OF BIO X CELL IN HONG KONG.

Contact us
Share This